Dual-acting therapeutic proteins for intraocular use

Matthew Collins; Sahar Awwad; Nkiru Ibeanu; Peng T Khaw; David Guiliano; Steve Brocchini; Hanieh Khalili

doi:10.1016/j.drudis.2020.10.025

Dual-acting therapeutic proteins for intraocular use

Drug Discov Today. 2021 Jan;26(1):44-55. doi: 10.1016/j.drudis.2020.10.025. Epub 2020 Nov 1.

Authors

Matthew Collins¹, Sahar Awwad², Nkiru Ibeanu², Peng T Khaw³, David Guiliano⁴, Steve Brocchini⁵, Hanieh Khalili⁶

Affiliations

¹ School of Health, Sport and Bioscience, University of East London, London, E15 4LZ, UK; School of Pharmacy, University College London, London, WC1N 1AX, UK.
² School of Pharmacy, University College London, London, WC1N 1AX, UK; National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, EC1V 9EL, UK.
³ National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, EC1V 9EL, UK.
⁴ School of Health, Sport and Bioscience, University of East London, London, E15 4LZ, UK.
⁵ School of Pharmacy, University College London, London, WC1N 1AX, UK.
⁶ School of Health, Sport and Bioscience, University of East London, London, E15 4LZ, UK; School of Pharmacy, University College London, London, WC1N 1AX, UK. Electronic address: H.khalili@uel.ac.uk.

PMID: 33137484
DOI: 10.1016/j.drudis.2020.10.025

Abstract

Intravitreally injected antibody-based medicines have revolutionised the treatment of retinal disease. Bispecific and dual-functional antibodies and therapeutic proteins have the potential to further increase the efficacy of intraocular medicines.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Angiogenesis Inhibitors / pharmacology
Anti-Inflammatory Agents / pharmacology
Antibodies, Bispecific / pharmacology*
Biological Products / pharmacology
Drug Development
Humans
Intravitreal Injections*
Retinal Diseases* / drug therapy
Retinal Diseases* / immunology
Retinal Diseases* / physiopathology

Substances

Angiogenesis Inhibitors
Anti-Inflammatory Agents
Antibodies, Bispecific
Biological Products

Grants and funding

G0801650/MRC_/Medical Research Council/United Kingdom